Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE in Germany and Austria 20. Juni 2023 N. Harbeck , R. Bartsch , V. Müller , M. Balic , D. Egle , E. Schumacher-Wulf , M. Angerer , A. Nusch , C. Uleer , M. Welslau , J. Radosa , D. Wrobel , R. de Buhr , M. Glasstetter , J. Hanselmann , C. Hogrefe , N. Marschner ,K. Gratzke , A. Welt Download Genetic alterations with potential impact on PD-(L)1 targeted treatment in various cancer entities – Biobank research project of the INFINITY registry Hillebrand LE, Vannier C, Jermann PM , Matter M, Läubli H, Grebhardt S, Wright PR, Woerner SM, Kansenda B, Marschner N, Potthoff K. Weiterlesen The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice Martens UM, Schröder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, Zaiss M, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Zacharias S, Marschner… Weiterlesen